Kestra Advisory Services LLC Cuts Stock Holdings in Zoetis Inc. $ZTS

Key Points

• Kestra Advisory Services LLC reduced its holdings in Zoetis Inc. by 11.5%, owning 39,598 shares valued at approximately $6.52 million after selling 5,162 shares in the first quarter.
• Several institutional investors increased their stakes in Zoetis, with notable boosts such as Bfsg LLC enhancing its position by 614.6% in the same quarter.
• Zoetis reported an earnings per share of $1.76 for the last quarter, exceeding the consensus estimate by $0.14, alongside a revenue increase of 4.2% year-over-year.

Kestra Advisory Services LLC decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 11.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,598 shares of the company's stock after selling 5,162 shares during the quarter. Kestra Advisory Services LLC's holdings in Zoetis were worth $6,520,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Navigoe LLC purchased a new position in shares of Zoetis during the fourth quarter worth about $30,000. Cornerstone Planning Group LLC boosted its stake in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after buying an additional 88 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its stake in Zoetis by 87.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after buying an additional 120 shares in the last quarter. Sound Income Strategies LLC boosted its stake in Zoetis by 141.4% in the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after buying an additional 164 shares in the last quarter. Finally, Bfsg LLC boosted its stake in Zoetis by 614.6% in the first quarter. Bfsg LLC now owns 293 shares of the company's stock worth $48,000 after buying an additional 252 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the transaction, the executive vice president directly owned 15,129 shares in the company, valued at $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.18% of the stock is owned by insiders.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $155.1040 on Tuesday. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The business has a fifty day moving average price of $153.66 and a 200-day moving average price of $158.30. The company has a market capitalization of $68.74 billion, a PE ratio of 26.70, a PEG ratio of 2.51 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same period last year, the company earned $1.56 earnings per share. The company's revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ZTS shares. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. UBS Group decreased their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Piper Sandler upped their target price on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Finally, Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and decreased their target price for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $202.43.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.